GlassScriptPhysician profile
Varol S Togay
NPI 1104938505
$8,406.72
in general payments reported to CMS, 2019-2025
22 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $1,962 · 2021: $652 · 2022: $2,034 · 2023: $1,022 · 2024: $677 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,969 · Travel and Lodging: $79.21 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,969.24 |
| Travel and Lodging | $79.21 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,130.22 | 2019-2020 | |
| Medtronic, INC. | $1,603.35 | 2021-2025 | Affera Mapping System, Na, Micra |
| Cardiofocus, INC. | $1,404.56 | 2022-2023 | Heartlight System |
| Abbott Laboratories | $906.91 | 2019-2025 | Ensite Precision, Perclose Proglide, Na |
| Boston Scientific Corporation | $720.16 | 2019-2025 | Watchman Flx, Watchman Access System, Farapulse |
| Biotronik INC. | $548.64 | 2022-2025 | Solia, Amvia Edge, Pamira |
| Kiniksa Pharmaceuticals International, Plc | $183.11 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $158.33 | 2020-2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f, Cardiva Vascade Mvp Vvcs 6-12f |
| Astrazeneca Pharmaceuticals LP | $149.62 | 2022-2024 | Farxiga |
| Treace Medical Concepts, INC. | $140.36 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $64.11 | 2019-2025 | Lifevest |
| Pfizer INC. | $61.25 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $50.75 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $43.59 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $42.12 | 2025 | Wegovy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $41.23 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $34.10 | 2023-2025 | Camzyos |
| Impulse Dynamics (USA) INC. | $29.53 | 2023 | Optimizer |
| Edwards Lifesciences Corporation | $28.59 | 2025 | Sapien 3 Ultra Resilia |
| Heartflow, INC. | $23.27 | 2023 | Ffrct |
| Irhythm Technologies, INC. | $22.52 | 2024 | Zio Xt Patch, Zio Monitor |
| Biosense Webster, INC. | $20.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varol Togay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.